These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

728 related articles for article (PubMed ID: 29137626)

  • 21. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013.
    Zhang L; Meng Q; Chen S; Zhang M; Chen B; Wu B; Yan G; Wang X; Jia Z
    Clin Microbiol Infect; 2018 Apr; 24(4):381-388. PubMed ID: 28712668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study.
    Cox H; Goig GA; Salaam-Dreyer Z; Dippenaar A; Reuter A; Mohr-Holland E; Daniels J; Cudahy PGT; Nicol MP; Borrell S; Reinhard M; Doetsch A; Beisel C; Gagneux S; Warren RM; Furin J
    J Clin Microbiol; 2022 Mar; 60(3):e0236221. PubMed ID: 35170980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study.
    Bastard M; Sanchez-Padilla E; du Cros P; Khamraev AK; Parpieva N; Tillyashaykov M; Hayrapetyan A; Kimenye K; Khurkhumal S; Dlamini T; Perez SF; Telnov A; Hewison C; Varaine F; Bonnet M
    PLoS One; 2018; 13(3):e0193491. PubMed ID: 29518098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical evolution of a group of patients with multidrug-resistant TB treated at a referral center in the city of Rio de Janeiro, Brazil.
    Siqueira HR; Freitas FA; Oliveira DN; Barreto AM; Dalcolmo MP; Albano RM
    J Bras Pneumol; 2009 Jan; 35(1):54-62. PubMed ID: 19219331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China.
    Xu C; Pang Y; Li R; Ruan Y; Wang L; Chen M; Zhang H
    J Infect; 2018 Apr; 76(4):348-353. PubMed ID: 29374587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection.
    Bonnet M; Pardini M; Meacci F; Orrù G; Yesilkaya H; Jarosz T; Andrew PW; Barer M; Checchi F; Rinder H; Orefici G; Rüsch-Gerdes S; Fattorini L; Oggioni MR; Melzer J; Niemann S; Varaine F
    PLoS One; 2011; 6(8):e23081. PubMed ID: 21886778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries.
    Günther G; van Leth F; Alexandru S; Altet N; Avsar K; Bang D; Barbuta R; Bothamley G; Ciobanu A; Crudu V; Danilovits M; Dedicoat M; Duarte R; Gualano G; Kunst H; de Lange W; Leimane V; McLaughlin AM; Magis-Escurra C; Muylle I; Polcová V; Popa C; Rumetshofer R; Skrahina A; Solodovnikova V; Spinu V; Tiberi S; Viiklepp P; Lange C;
    Am J Respir Crit Care Med; 2018 Aug; 198(3):379-386. PubMed ID: 29509468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of bedaquiline containing all oral longer regimens in treating multidrug/rifampicin resistant tuberculosis in Pakistan.
    Khan A; Khan AH; Ahmad N; Ghafoor A
    J Infect Public Health; 2024 Sep; 17(9):102522. PubMed ID: 39173557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
    Lee H; Jeong BH; Park HY; Jeon K; Huh HJ; Lee NY; Koh WJ
    Antimicrob Agents Chemother; 2016 Jan; 60(1):471-7. PubMed ID: 26525801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cross-sectional study of tuberculosis drug resistance among previously treated patients in a tertiary hospital in Accra, Ghana: public health implications of standardized regimens.
    Forson A; Kwara A; Kudzawu S; Omari M; Otu J; Gehre F; de Jong B; Antonio M
    BMC Infect Dis; 2018 Apr; 18(1):149. PubMed ID: 29606091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of multidrug-resistant tuberculosis in Thailand.
    Maranetra KN
    Chemotherapy; 1996; 42 Suppl 3():10-5; discussion 30-3. PubMed ID: 8980862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study.
    Javaid A; Ullah I; Masud H; Basit A; Ahmad W; Butt ZA; Qasim M
    Clin Microbiol Infect; 2018 Jun; 24(6):612-617. PubMed ID: 28970158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
    BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China.
    Chen Y; Yuan Z; Shen X; Wu J; Wu Z; Xu B
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
    Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
    BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid drug susceptibility testing and treatment outcomes for multidrug-resistant tuberculosis in Peru.
    Obregón G; Zevallos K; Alarcón V; Puyén ZM; Chávez Inagaki O; Mendoza-Ticona A; Alarcón-Arrascue E; Heldal E; Moore DAJ
    Int J Tuberc Lung Dis; 2018 Nov; 22(11):1350-1357. PubMed ID: 30355416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
    Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan.
    van den Hof S; Tursynbayeva A; Abildaev T; Adenov M; Pak S; Bekembayeva G; Ismailov S
    Int J Tuberc Lung Dis; 2013 Apr; 17(4):526-31. PubMed ID: 23485387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluoroquinolones for the treatment of tuberculosis in children.
    Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
    Tuberculosis (Edinb); 2015 May; 95(3):229-45. PubMed ID: 25797610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.